JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

Claire Harrison, Jean Jacques Kiladjian, Haifa Kathrin Al-Ali, Heinz Gisslinger, Roger Waltzman, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S. Hunter, Richard Levy, Laurent Knoops, Francisco Cervantes, Alessandro M. Vannucchi, Tiziano Barbui, Giovanni Barosi

Research output: Contribution to journalArticle

931 Citations (Scopus)

Abstract

BACKGROUND: Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis. METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy. The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% reduction in spleen volume at week 48 and at week 24, respectively, as assessed with the use of magnetic resonance imaging or computed tomography. RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% reduction in spleen volume at week 48, as compared with 0% in the group receiving the best available therapy (P

Original languageEnglish
Pages (from-to)787-798
Number of pages12
JournalNew England Journal of Medicine
Volume366
Issue number9
DOIs
Publication statusPublished - Mar 1 2012

Fingerprint

Janus Kinases
Primary Myelofibrosis
Janus Kinase 1
Spleen
Janus Kinase 2
Essential Thrombocythemia
Therapeutics
Polycythemia Vera
Tomography
Magnetic Resonance Imaging
INCB018424
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Harrison, C., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., ... Barosi, G. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366(9), 787-798. https://doi.org/10.1056/NEJMoa1110556

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. / Harrison, Claire; Kiladjian, Jean Jacques; Al-Ali, Haifa Kathrin; Gisslinger, Heinz; Waltzman, Roger; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S.; Levy, Richard; Knoops, Laurent; Cervantes, Francisco; Vannucchi, Alessandro M.; Barbui, Tiziano; Barosi, Giovanni.

In: New England Journal of Medicine, Vol. 366, No. 9, 01.03.2012, p. 787-798.

Research output: Contribution to journalArticle

Harrison, C, Kiladjian, JJ, Al-Ali, HK, Gisslinger, H, Waltzman, R, Stalbovskaya, V, McQuitty, M, Hunter, DS, Levy, R, Knoops, L, Cervantes, F, Vannucchi, AM, Barbui, T & Barosi, G 2012, 'JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis', New England Journal of Medicine, vol. 366, no. 9, pp. 787-798. https://doi.org/10.1056/NEJMoa1110556
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine. 2012 Mar 1;366(9):787-798. https://doi.org/10.1056/NEJMoa1110556
Harrison, Claire ; Kiladjian, Jean Jacques ; Al-Ali, Haifa Kathrin ; Gisslinger, Heinz ; Waltzman, Roger ; Stalbovskaya, Viktoriya ; McQuitty, Mari ; Hunter, Deborah S. ; Levy, Richard ; Knoops, Laurent ; Cervantes, Francisco ; Vannucchi, Alessandro M. ; Barbui, Tiziano ; Barosi, Giovanni. / JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. In: New England Journal of Medicine. 2012 ; Vol. 366, No. 9. pp. 787-798.
@article{c142ad87ffed4c44bb51e24fb022739c,
title = "JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis",
abstract = "BACKGROUND: Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis. METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy. The primary end point and key secondary end point of the study were the percentage of patients with at least a 35{\%} reduction in spleen volume at week 48 and at week 24, respectively, as assessed with the use of magnetic resonance imaging or computed tomography. RESULTS: A total of 28{\%} of the patients in the ruxolitinib group had at least a 35{\%} reduction in spleen volume at week 48, as compared with 0{\%} in the group receiving the best available therapy (P",
author = "Claire Harrison and Kiladjian, {Jean Jacques} and Al-Ali, {Haifa Kathrin} and Heinz Gisslinger and Roger Waltzman and Viktoriya Stalbovskaya and Mari McQuitty and Hunter, {Deborah S.} and Richard Levy and Laurent Knoops and Francisco Cervantes and Vannucchi, {Alessandro M.} and Tiziano Barbui and Giovanni Barosi",
year = "2012",
month = "3",
day = "1",
doi = "10.1056/NEJMoa1110556",
language = "English",
volume = "366",
pages = "787--798",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "9",

}

TY - JOUR

T1 - JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

AU - Harrison, Claire

AU - Kiladjian, Jean Jacques

AU - Al-Ali, Haifa Kathrin

AU - Gisslinger, Heinz

AU - Waltzman, Roger

AU - Stalbovskaya, Viktoriya

AU - McQuitty, Mari

AU - Hunter, Deborah S.

AU - Levy, Richard

AU - Knoops, Laurent

AU - Cervantes, Francisco

AU - Vannucchi, Alessandro M.

AU - Barbui, Tiziano

AU - Barosi, Giovanni

PY - 2012/3/1

Y1 - 2012/3/1

N2 - BACKGROUND: Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis. METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy. The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% reduction in spleen volume at week 48 and at week 24, respectively, as assessed with the use of magnetic resonance imaging or computed tomography. RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% reduction in spleen volume at week 48, as compared with 0% in the group receiving the best available therapy (P

AB - BACKGROUND: Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis. METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy. The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% reduction in spleen volume at week 48 and at week 24, respectively, as assessed with the use of magnetic resonance imaging or computed tomography. RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% reduction in spleen volume at week 48, as compared with 0% in the group receiving the best available therapy (P

UR - http://www.scopus.com/inward/record.url?scp=84857837774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857837774&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1110556

DO - 10.1056/NEJMoa1110556

M3 - Article

C2 - 22375970

AN - SCOPUS:84857837774

VL - 366

SP - 787

EP - 798

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 9

ER -